ArticleParasites & vectors2025
Disruption of mitochondrial function in blood and sexual stages of Plasmodium falciparum by ferulenol.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antiplasmodial Compounds fromInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria continues to be a significant global health challenge, necessitating the development of novel antimalarial compounds. This study explores the effects of ferulenol on multiple lifecycle stages of Plasmodium falciparum. Ferulenol has been identified as a promising antimalarial candidate, demonstrating high efficacy in inhibiting asexual blood-stage parasites at low micromolar concentrations. However, its effects on other parasite stages remain unexplored, despite its mitochondrial target being critical for sexual stage development. This study aims to investigate ferulenol's potential as a dual-target antimalarial by assessing its effects on development of asexual blood-stage and transmission precursor-stage parasites.
methodsFalciparum malaria parasites were cultured in vitro and incubated with or without ferulenol. Effects of the treatment on the development of the asexual blood-stage, early-stage gametocyte, late-stage gametocyte, and gamete formation were assessed using light microscopy. The impact of ferulenol on mitochondrial membrane potential was investigated using JC-1 staining and analyzed by fluorescence microscopy.
resultsThe highest dose of ferulenol inhibited asexual blood-stage proliferation by 88%, early-stage gametocyte development by 82%, and stage V gametocyte maturation at about 90%. Moreover, the effect of ferulenol was more pronounced on male gamete formation than on female gamete formation, with the development inhibited at 81% and 27%, respectively.
conclusionsThese findings position ferulenol as a promising dual antimalarial activity on asexual blood-stage and gametocyte stages, which could lead the compound to disrupt both severity and transmission of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.